Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-779788 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BMS-779788 or Placebo (Arm 1) | ACTIVE_COMPARATOR | - |
| BMS-779788 or Placebo (Arm 2) | ACTIVE_COMPARATOR | - |
| BMS-779788 or Placebo (Arm 3) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-779788 | DRUG | Oral Solution, Oral, 1 mg, Once daily, 7 days |
| Placebo | DRUG | Oral Solution, Oral, 0 mg, Once daily, 7 days |
Inclusion Criteria: * Men and women (not of child bearing potential) ages 18 to 45 * Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations Exclusion Criteria: * Women of child bearin...
Top 10 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 7 | PHASE3 | Ziltivekimab, Zenagamtide |
| Eli Lilly and Company | LLY | 6 | PHASE3 | Lepodisiran, Retatrutide, Muvalaplin, Orforglipron, Clazakizumab |
| Novartis AG Sponsored ADR | NVS | 8 | PHASE3 | Inclisiran, Pelacarsen |
| Amgen Inc. | AMGN | 4 | PHASE3 | Olpasiran, Maridebart cafraglutide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide |
| NewAmsterdam Pharma Company N.V. | NAMS | 2 | PHASE3 | Obicetrapib |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Genentech, Inc. | RHHBY | 1 | PHASE2 | Selnoflast |
| Verve Therapeutics, Inc. | VERV | 2 | PHASE2 | VERVE-102 |
BMS-779788 is an investigational small molecule developed by Bristol-Myers Squibb for atherosclerosis, a cardiovascular condition. It is a Phase 1 clinical candidate and has not been approved for any indication. The compound was studied in a single completed Phase 1 trial of 25 healthy volunteers.
BMS-779788 targets NR1H2, also known as liver X receptor beta, and acts as an agonist at this receptor. NR1H2 is a nuclear receptor involved in lipid metabolism and inflammatory pathways. Agonism of NR1H2 is the intended mechanism for the atherosclerosis indication.
Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY, is the developer of BMS-779788. The company sponsored the Phase 1 study of the compound in healthy subjects.
BMS-779788 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The only recorded trial is a completed Phase 1 study, and no active trials are ongoing.
BMS-779788 was evaluated in one completed Phase 1 trial, NCT00836602, titled a multiple-dose study to evaluate safety, pharmacokinetics and pharmacodynamics in healthy subjects. The trial enrolled 25 participants in Australia, was randomized, double-blind, and active-controlled, and has completed.